ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
3.985
+0.065 (1.66%)
Feb 12, 2026, 1:25 PM EST - Market open
ADC Therapeutics Employees
As of December 31, 2024, ADC Therapeutics had 265 total employees, including 263 full-time and 2 part-time employees. The number of employees decreased by 9 or -3.28% compared to the previous year.
Employees
265
Change (1Y)
-9
Growth (1Y)
-3.28%
Revenue / Employee
$283,808
Profits / Employee
-$629,966
Market Cap
493.65M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 265 | -9 | -3.28% | 263 | 2 |
| Dec 31, 2023 | 274 | -43 | -13.56% | 273 | 1 |
| Dec 31, 2022 | 317 | 5 | 1.60% | 317 | 0 |
| Dec 31, 2021 | 312 | 104 | 50.00% | 312 | 0 |
| Dec 31, 2020 | 208 | - | - | 208 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Lyell Immunopharma | 300 |
| 4D Molecular Therapeutics | 227 |
| Prothena Corporation | 163 |
| Invivyd | 100 |
| Ocugen | 95 |
| Neumora Therapeutics | 95 |
| Verastem | 78 |
| Lexeo Therapeutics | 61 |
ADCT News
- 9 days ago - ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PRNewsWire
- 27 days ago - ADC Therapeutics SA (ADCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates - PRNewsWire
- 5 weeks ago - ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 5 weeks ago - ADC Therapeutics Announces New Employee Inducement Grant - PRNewsWire
- 2 months ago - ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript - Seeking Alpha
- 2 months ago - ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma - PRNewsWire
- 2 months ago - ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial - PRNewsWire